凝血酶原复合浓缩物市场机会、成长动力、产业趋势分析与预测 2024 - 2032

Prothrombin Complex Concentrate Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: 2024年10月22日 | 出版商:

Global Market Insights Inc. | 英文 131 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023 年，全球凝血酶原复合浓缩物市场价值为21 亿美元，预计2024 年至2032 年复合年增长率为9.4%。不断增加推动的。凝血障碍的激增极大地促进了全球 PCC 市场的扩张。随着出血性疾病和后天性凝血障碍等疾病变得越来越常见，对 PCC 等有效、快速治疗方案的需求也越来越大。维生素 K 缺乏、肝臟疾病和抗凝血药物的广泛使用等因素进一步强调了 PCC 的重要性，特别是在需要快速介入的紧急情况下。

市场依产品类型分为4因素PCC和3因素PCC。 2023 年，四因子 PCC 细分市场引领市场，创造约 12 亿美元。该产品由于起效快且在治疗各种病症方面具有多功能性（包括逆转直接口服抗凝血剂），因此通常在重症监护环境中成为首选。各卫生组织临床指引对四因素 PCC 的大力认可巩固了其在凝血相关治疗领域的地位，进一步提高了其市场份额。

从应用角度来看，到2023 年，获得性凝血因子缺乏症领域占据了近一半的市场份额。为普遍。这种较高的发病率推动了临床环境中对 PCC 的需求，在这些环境中，及时治疗至关重要，特别是在手术或创伤病例中。 2023 年，北美成为 PCC 市场的领先地区，收入达 7.883 亿美元，预计到 2032 年将达到 17 亿美元。。此外，美国和加拿大先进的医疗基础设施支援 PCC 治疗的有效使用和监测，确保患者得到及时、有效率的照护。

市场范围
开始年份	2023年
预测年份	2024-2032
起始值	21亿美元
预测值	47 亿美元
复合年增长率	9.4%

这种不断增长的市场格局凸显了 PCC 在治疗凝血障碍和改善患者治疗效果方面的重要性。

产业生态系统分析
产业影响力
- 成长动力
  - 凝血障碍的发生率增加
  - 对血浆相关疗法的需求不断增长
  - 技术创新
  - 研究与开发的进步
- 产业陷阱与挑战
  - 来自替代品的激烈竞争
成长潜力分析
监管环境
技术景观
报销场景
定价分析
- 按地区
- 副产品
未来市场趋势
专利分析
利润率分析
管道分析
临床试验情况
差距分析
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按产品类型，2021 - 2032

主要趋势
4因素PCC
三因素PCC

第 6 章：市场估计与预测：按应用分类，2021 - 2032

主要趋势
后天性凝血因子缺乏症
先天性凝血因子缺乏症
其他应用

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

主要趋势
医院
门诊手术中心
其他最终用户

第 8 章：市场估计与预测：按地区划分，2021 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 义大利
- 西班牙
- 荷兰
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋

第 9 章：公司简介

CSL
Baxter
Emergent BioSolutions
Grifols Biologicals
Intas Pharmaceuticals
Kedrion Biopharma
LFB Group
Octapharma
Pfizer
Prothya Biosolutions
Takeda Pharmaceuticals

简介目录

Product Code: 11940

The Global Prothrombin Complex Concentrate Market was valued at USD 2.1 billion in 2023 and is projected to grow at 9.4% CAGR from 2024 to 2032. This growth is primarily fueled by the rising prevalence of coagulation disorders and the increasing demand for plasma-derived therapies. The surge in coagulation disorders significantly contributes to the expansion of the PCC market worldwide. As conditions such as bleeding disorders and acquired coagulation disorders become more common, the need for effective and rapid treatment options like PCC has intensified. Factors such as vitamin K deficiency, liver diseases, and the widespread use of anticoagulant medications have further emphasized the importance of PCC, especially in emergency situations where quick intervention is essential.

The market is categorized by product type into 4-factor PCC and 3-factor PCC. In 2023, the 4-factor PCC segment led the market, generating approximately USD 1.2 billion. This product is often preferred in critical care settings due to its rapid onset of action and versatility in treating various conditions, including the reversal of direct oral anticoagulants. The strong endorsement of 4-factor PCC by clinical guidelines from various health organizations reinforces its position in coagulation-related treatments, further enhancing its market share.

From an application perspective, the segment for acquired coagulation factor deficiency captured nearly half of the market share in 2023. This type of disorder, often linked to conditions such as vitamin K deficiency or the effects of anticoagulant therapies, is more prevalent than congenital disorders. This higher incidence drives the demand for PCC in clinical settings where prompt treatment is essential, particularly during surgeries or trauma cases. North America emerged as the leading region in the PCC market in 2023, with revenues amounting to USD 788.3 million and expectations to reach USD 1.7 billion by 2032. The increasing prevalence of coagulation disorders, particularly in older populations, is a significant driver of PCC demand. Moreover, the advanced healthcare infrastructure in the U.S. and Canada supports the effective use and monitoring of PCC treatments, ensuring patients receive timely and efficient care.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$2.1 Billion
Forecast Value	$4.7 Billion
CAGR	9.4%

This growing market landscape highlights the importance of PCC in managing coagulation disorders and enhancing patient outcomes.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increased incidence of coagulation disorders
  - 3.2.1.2 Growing demand for plasma-related therapies
  - 3.2.1.3 Technological innovations
  - 3.2.1.4 Advancements in research and development
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Intense competition from alternatives
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Reimbursement scenario
3.7 Pricing analysis
- 3.7.1 By region
- 3.7.2 By product
3.8 Future market trends
3.9 Patent analysis
3.10 Profit margin analysis
3.11 Pipeline analysis
3.12 Clinical trial landscape
3.13 Gap analysis
3.14 Porter's analysis
3.15 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 4-factor PCC
5.3 3-factor PCC

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Acquired coagulation factor deficiency
6.3 Congenital coagulation factor deficiency
6.4 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Ambulatory surgical centers
7.4 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Netherlands
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE